Literature DB >> 33319489

Functional inhibition of heat shock protein 70 by VER-155008 suppresses pleural mesothelioma cell proliferation via an autophagy mechanism.

Kosuke Sakai1,2, Maya Inoue1, Shintaro Mikami1, Hiroaki Nishimura1, Yoshiki Kuwabara1, Akitoshi Kojima1, Maiko Toda1, Yumiko Ogawa-Kobayashi1,2, Satoshi Kikuchi1, Yusuke Hirata1, Yuriko Mikami-Saito1, Hiroyuki Kyoyama1, Gaku Moriyama1,2, Michio Shiibashi3, Masahiro Seike2, Akihiko Gemma2, Kazutsugu Uematsu1.   

Abstract

BACKGROUND: Pleural mesothelioma, a devastating asbestos-associated malignancy, urgently requires a novel effective therapy. Heat shock protein 70 (HSP70), which is synthesized in the cell response to protein damage, is expected to be a new target for antitumor treatment. In addition to its well-known protein refolding function, HSP70 regulates cell proliferation through different pathways, including PI3K/AKT/mTOR, and autophagy in malignant cells. In this study, we attempted to clarify the effects of VER-155008, an HSP70 inhibitor, on pleural mesothelioma.
METHODS: Human pleural mesothelioma cell lines 211H, H2452 and H28 were cultured with VER-155008, and protein expression, cell proliferation, colony formation, cell cycle, synergistic effect with cisplatin, and autophagy induction were analyzed.
RESULTS: In mesothelioma cell lines, VER-155008 (5.0 μM or more) inhibited cell growth and colony formation, accompanied by G1 cell cycle arrest. According to western blot analysis, VER-155008 reduced p-AKT expression. However, VER-155008 failed to show a synergistic effect with cisplatin on cell growth. Mesothelioma cells transfected with the novel plasmid pMRX-IP-GFP-LC3-RFP-LC3ΔG, which was developed for the quantitative and statistical estimation of macroautophagy, showed enhanced macroautophagy upon treatment with VER-155008 and gefitinib which is an EGFR-tyrosine kinase inhibitor. In addition, fetal bovine serum deprivation induced macroautophagy was further enhanced by VER-155008.
CONCLUSIONS: On the basis of these results, functional HSP70 inhibition by VER-155008 suppressed cell growth in pleural mesothelioma cells, accompanied by enhanced macroautophagy. HSP70 inhibition is thus expected to become a new strategy for treating mesothelioma. KEY POINTS: Significant findings of the study In pleural mesothelioma cells, inhibition of HSP70 function by VER-155008 suppressed cell proliferation accompanied by induction of autophagy which was synergistically enhanced under the starvation condition, whereas gefitinib, an EGFR-TKI, did not show the same synergistic effect in autophagy. What this study adds The inhibition of HSP70 induced autophagy and suppressed cell proliferation in mesothelioma cells.
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Gefitinib; VER-155008; heat shock protein 70; macroautophagy; pleural mesothelioma

Year:  2020        PMID: 33319489      PMCID: PMC7882380          DOI: 10.1111/1759-7714.13784

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  38 in total

1.  Inhibition of the JNK/Bim pathway by Hsp70 prevents Bax activation in UV-induced apoptosis.

Authors:  Hui Li; Lei Liu; Da Xing; Wei R Chen
Journal:  FEBS Lett       Date:  2010-10-29       Impact factor: 4.124

2.  Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model.

Authors:  Takehiko Murayama; Ken Takahashi; Yuji Natori; Norio Kurumatani
Journal:  Am J Ind Med       Date:  2006-01       Impact factor: 2.214

Review 3.  Autophagy-dependent cell death - where, how and why a cell eats itself to death.

Authors:  Shani Bialik; Santosh K Dasari; Adi Kimchi
Journal:  J Cell Sci       Date:  2018-09-20       Impact factor: 5.285

4.  Methods in mammalian autophagy research.

Authors:  Noboru Mizushima; Tamotsu Yoshimori; Beth Levine
Journal:  Cell       Date:  2010-02-05       Impact factor: 41.582

5.  Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis.

Authors:  M Verheij; R Bose; X H Lin; B Yao; W D Jarvis; S Grant; M J Birrer; E Szabo; L I Zon; J M Kyriakis; A Haimovitz-Friedman; Z Fuks; R N Kolesnick
Journal:  Nature       Date:  1996-03-07       Impact factor: 49.962

6.  VER-155008, a small molecule inhibitor of HSP70 with potent anti-cancer activity on lung cancer cell lines.

Authors:  Wei Wen; Wuxin Liu; Yongfeng Shao; Liang Chen
Journal:  Exp Biol Med (Maywood)       Date:  2014-03-27

7.  Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study.

Authors:  E Małusecka; A Zborek; S Krzyzowska-Gruca; Z Krawczyk
Journal:  Anticancer Res       Date:  2001 Mar-Apr       Impact factor: 2.480

Review 8.  PI3K-Akt pathway: its functions and alterations in human cancer.

Authors:  M Osaki; M Oshimura; H Ito
Journal:  Apoptosis       Date:  2004-11       Impact factor: 4.677

Review 9.  Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Authors:  Jiyong Liang; Joyce M Slingerland
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

10.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

View more
  3 in total

Review 1.  The heat shock response and small molecule regulators.

Authors:  Margaret K Kurop; Cormac M Huyen; John H Kelly; Brian S J Blagg
Journal:  Eur J Med Chem       Date:  2021-09-13       Impact factor: 6.514

Review 2.  The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma.

Authors:  Valeria Ramundo; Giada Zanirato; Elisabetta Aldieri
Journal:  Int J Mol Sci       Date:  2021-11-11       Impact factor: 5.923

Review 3.  Advances in the study of HSP70 inhibitors to enhance the sensitivity of tumor cells to radiotherapy.

Authors:  Sihan Du; Ying Liu; Yuan Yuan; Yuran Wang; Yanfang Chen; Shuai Wang; Yuhua Chi
Journal:  Front Cell Dev Biol       Date:  2022-08-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.